The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype

Published:2022-07-18 Issue:1 Volume:62 Page:90-100
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Molecular Carcinogenesis

Author:

Chen Xi¹,Adhikary Gautam¹,Newland John J.²,Xu Wen¹,Ma Emily¹,Naselsky Warren²,Eckert Richard L.¹³⁴^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Biology University of Maryland School of Medicine Baltimore Maryland USA

2. Department of Surgery – Division of Thoracic Oncology University of Maryland School of Medicine Baltimore Maryland USA

3. Department of Dermatology University of Maryland School of Medicine Baltimore Maryland USA

4. Marlene and Stewart Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine Baltimore Maryland USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23446

Reference53 articles.

1. Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target

2. Transglutaminase is a tumor cell and cancer stem cell survival factor

3. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival

4. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition

5. Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting transglutaminase 2 mediated exostosin glycosyltransferase 1 signaling in liver cancer stem cells with acyclic retinoid;Cell Death & Disease;2023-06-13

2. Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype;Molecular Cancer Research;2023-05-25

3. Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotype;Molecular Carcinogenesis;2022-10-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3